Resveratrol ameliorates diabetes‐related metabolic changes via activation of AMP‐activated protein kinase and its downstream targets in db/db mice
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Scope: This study investigated the effects of resveratrol (RV) on diabetes‐related metabolic changes in a spontaneous model of type 2 diabetes, as well as activation of AMP‐activated protein kinase (AMPK) and downstream targets. Methods and results: C 57 BL/K s J‐db/db mice were fed a normal diet with RV (0.005% and 0.02%, w/w) or rosiglitazone (RG, 0.001%, w/w) for 6 weeks. Both doses of RV significantly decreased blood glucose, plasma free fatty acid, triglyceride, apo B/apo AІ levels and increased plasma adiponectin levels. RV activated AMPK and downstream targets leading to decreased blood HbA1c levels, hepatic gluconeogenic enzyme activity, and hepatic glycogen, while plasma insulin levels, pancreatic insulin protein, and skeletal muscle GLUT4 protein were higher after RV supplementation. The high RV dose also significantly increased hepatic glycolytic gene expression and enzyme activity, along with skeletal muscle glycogen synthase protein expression, similar to RG. Furthermore, RV dose dependently decreased hepatic triglyceride content and phosphorylated I kappa B kinase (p‐IKK) protein expression, while hepatic uncoupling protein (UCP) and skeletal muscle UCP expression were increased. Conclusion: RV potentiates improving glycemic control, glucose uptake, and dyslipidemia, as well as protecting against pancreatic β‐cell failure in a spontaneous type 2 diabetes model. Dietary RV has potential as an antidiabetic agent via activation of AMPK and its downstream targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245 · cited 1×
“IKK also inhibits upstream signaling proteins in the insulin signaling pathway, therefore can improve modulate glucose uptake [45].”
BackgroundThe use of animal models in diabetes research
King, A. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01911.x · Cited by 1,303
Cline, G. W., Petersen, K. F., Krssak, M., Shen, J., Hundal, R. S., Trajanoski, Z., Inzucchi, S., Dresner, A., Rothman, D. L., & Shulman, G. I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410404 · Cited by 675
Resveratrol and health—A comprehensive review of human clinical trials
Smoliga, J. M., Baur, J. A., & Hausenblas, H. A. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100143 · Cited by 594
Yoon, M. J., Lee, G. Y., Chung, J.-J., Ahn, Y. H., Hong, S. H., & Kim, J. B. (2006) · Diabetes · doi:10.2337/db05-1322 · Cited by 546 · cited 1×
“In the present study, plasma adiponectin levels were significantly higher in the RV-supplemented db/db mice, which was consistent with evidence that adiponectin also stimulates AMPK and PPAR activity in target tissues [42].”
BackgroundDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Elevated hepatic glucose production is a major contributor to hyperglycemia in type 2 diabetes [32].”
BackgroundRivera, L., Morón, R., Zarzuelo, A., & Galisteo, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.027 · Cited by 391 · cited 1×
“RV can also prevent hepatic lipid accumulation in vivo, in obese Zucker rats [7], and high-fat fed rodents [8, 9].”
BackgroundSensing of energy and nutrients by AMP-activated protein kinase
Hardie, D. G. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001925 · Cited by 372
Cited by
Antidiabetic Potential of Medicinal Plants and Their Active Components
Salehi, B., Ata, A., V. Anil Kumar, N., Sharopov, F., Ramírez-Alarcón, K., Ruiz-Ortega, A., Abdulmajid Ayatollahi, S., Valere Tsouh Fokou, P., Kobarfard, F., Amiruddin Zakaria, Z., et al. (2019) · Biomolecules · doi:10.3390/biom9100551 · Cited by 747
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F., García-Conesa, M., & Espín, J. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 449
Resveratrol and diabetes: from animal to human studies
Szkudelski, T., & Szkudelska, K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.013 · Cited by 354
Resveratrol and Its Effects on the Vascular System
Breuss, J. M., Atanasov, A. G., & Uhrin, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071523 · Cited by 328
Resveratrol: A miraculous natural compound for diseases treatment
Koushki, M., Amiri‐Dashatan, N., Ahmadi, N., Abbaszadeh, H., & Rezaei‐Tavirani, M. (2018) · Food Science & Nutrition · doi:10.1002/fsn3.855 · Cited by 316
Metadata
- Authors
- Do, G., Jung, U. J., Park, H., Kwon, E., Jeon, S., McGregor, R. A., & Choi, M.
- Venue
- Molecular Nutrition & Food Research
- Publisher
- Wiley
- Published
- 2012-06-20
- Volume
- 56
- Issue
- 8
- Pages
- 1282-1291
- ISSN
- 1613-4125 (ISSN-L)
- 1613-4133
- OpenAlex
- W2016645610
- Cited by
- 141
- References
- 11
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resveratrol ameliorates diabetes‐related metabolic changes via activation of AMP‐activated protein kinase and its downstream targets in db/db mice. https://app.cochat.ai/papers/10.1002/mnfr.201200067
- The paper
- Do, G., Jung, U. J., Park, H., Kwon, E., Jeon, S., McGregor, R. A., & Choi, M. (2012). Resveratrol ameliorates diabetes‐related metabolic changes via activation of AMP‐activated protein kinase and its downstream targets in db/db mice. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.201200067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.